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Abstract: Interferon-α, currently used for the treatment of hepatitis C, is associated with 
a substantially elevated risk of depression. However, not everyone who takes this drug becomes 
depressed, so it is important to understand what particular factors may make some individuals 
more ‘at risk’ of developing depression than others. Currently there is no consensus as to why 
interferon-induced depression occurs and the range of putative risk factors is wide and diverse. 
The identification of risk factors prior to treatment may allow identification of patients who will 
become depressed on interferon, allowing the possibility of improved treatment support and 
rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and 
we discuss the potential confounds within the research examined in order to better isolate the 
risk factors that may be important in the development of depression in these patients and which 
might help predict patients likely to become depressed on treatment. We suggest that interactions 
between psychobehavioral, genetic, and biological risk factors are of particular importance in 
the occurrence of depression in patients with hepatitis C taking interferon-α.
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Background
Hepatitis C virus (HCV) is a major cause of liver disease and death and affects 
∼170 million people worldwide.1 Recent epidemiological studies suggest more than 
90% of transmission in developed countries occurs through the sharing of nonsterilized 
needles and syringes in the intravenous drug-using population, ‘unknown’ sources, 
and ‘other’ sources such as dialysis, hemophilia, sexual transmission, and tattoos or 
piercing.2–5 Rates through blood transfusion are decreasing dramatically in the devel-
oped world due to improved screening for viruses in blood donations since the early 
1990s, although progress is somewhat slower in developing countries.2 Progression 
from initial infection to liver cirrhosis and cancer can take 20–30 years;6,7 thus, compli-
cations from chronic HCV infection are, therefore, anticipated to continue to increase,8 
with rates of cirrhosis doubling, liver-related deaths tripling, and HCV becoming the 
leading reason for liver transplantation.9
There is no vaccine for HCV; thus, the need for effective treatments for this 
infection is critical. Currently, the main Federal Drug Authority-approved   treatment 
for HCV is the use of the proinflammatory cytokine interferon-α (IFN-α), a 
  multifunctional pleiotropic protein with antiproliferative, antiviral, and immuno-
regulatory functions,10 which is usually used in combination with broad-spectrum 
antiviral   ribavirin.   Unfortunately, this treatment is only effective in ∼40%–80% of 
patients, with efficacy varying dramatically between genotypes.11,12 Treatment is also Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Similarities between MDD and sickness behavior36–39
Depression Sickness behavior
Somatic effects Fatigue/loss of energy
weight loss/weight gain
Appetite loss/appetite 
increase
insomnia/hypersomnia
Fatigue
weight loss
Anorexia
Sleep disorders
increased body 
temperature
Behavioral effects Depressed mood
Feelings of 
worthlessness/guilt
Loss of interest in activities
Anhedonia
inability to concentrate
Psychomotor agitation/
retardation
Recurrent thoughts of death
Depressed mood
Behavioral despair
Social withdrawal
Anhedonia
Cognitive 
impairment
Suppression motor 
behavior
Note: Similarities between a major depressive episode and sickness behavior.
Copyright © 2009, Les Laboratories Servier, Neuilly-sur-Seine, France. Adapted 
from Lotrich Fe. Major depression during interferon-alpha treatment: vulnerability 
and prevention. Dialogues Clin Neurosci. 2009;11(4):417–425.
expensive and has a well-documented profile of physical, 
behavioral, and psychiatric side effects, including flu-
like symptoms, fatigue, insomnia, depressed mood, and 
irritability,12–16 all of which could impact upon compliance. 
Depression is a particularly common side effect that may 
occur in up to 60% of patients,17,18 and in some rare cases, 
it may be associated with deliberate self-harm or suicide 
attempts.19,20 The neuropsychiatric side effects of IFN-α 
therapy are among the commonest causes of treatment 
discontinuation,21,22 and risk factors such as baseline psy-
chiatric symptoms and interpersonal problems can predict 
poor compliance.23 Identification of the risk factors that 
lead to neuropsychiatric side effects and the associated 
low adherence rates may help identify patients at risk who 
may then benefit from additional   psychological assessment 
and support.
Current treatment for IFN-α-induced depression involves 
the coadministration of selective serotonin reuptake inhibi-
tors (SSRIs), which have been shown to improve treatment 
  adherence in depressed patients.24 However, variations 
in   prescribing practice exist. Some clinicians wait for the 
depression to occur before prescribing these drugs, mean-
ing up to a month may pass before a reduction in depressive 
symptoms occurs.25 Other clinicians adopt a policy of pro-
phylactically administering SSRIs to reduce the occurrence 
of depression and depressive symptomology, with dose 
modification where necessary,26–28 but this means a large 
number of patients who do not need an SSRI could be pre-
scribed one. Where studies have identified ‘at-risk’ patients 
for prophylaxis of antidepressants and psychological support, 
these have both proven effective methods of reducing the 
occurrence of depression.29–31
In order to avoid depressive complications and associ-
ated treatment compliance risks, identification of risk factors 
for the subsequent development of depression could assist 
clinicians in deciding to coprescribe an antidepressant and 
psychological support at the start of antiviral treatment. Here, 
we provide an overview of data on HCV patients taking 
IFN-α in order to assess potential risk factors that affect the 
development of depression.
The main risk factors identified and investigated in this 
literature review can be divided into five main categories: 
biological, demographic, treatment related, genetic, and 
psychobehavioral. Here, we examine these categories and 
review evidence that these potential risk factors pose a suf-
ficiently substantive risk of depression that pretreatment 
support should be considered.
Methods
A literature search was conducted in PubMed using the key-
words ‘depression’, ‘interferon-α’, and ‘hepatitis C’. A total 
of 169 English, full-text, original research articles where rates 
of depression were assessed in the target population were then 
screened for their assessment of risk factors of depression. 
Those articles that used formal statistical analysis to assess 
possible risk factors were then broken down into five broad 
categories: biological, demographic, treatment related, genetic, 
and psychobehavioral. Once these categories were identified, 
further PubMed searches were conducted including category 
titles and subtitles as additional keywords. In total, 52 articles 
were assessed as part of the main review, and results from these 
articles are presented along with   supporting evidence.
Review of risk factors
Biological risk factors
Biological mechanisms
Many humans or animals administered with a cytokine 
develop a behavioral syndrome and set of somatic effects 
termed ‘sickness behavior’; these behaviors result in an altera-
tion of the motivational state of an organism so that it can 
preferentially respond to infections.32–34 In other words, the 
organism will have depressed functioning of mood, activity, 
and metabolism so that all of its energy is put into fighting 
illness. The observation that sickness behavior and depression 
share common features35 (see Table 1) has led many research-
ers to implicate raised levels of cytokines in the pathology of 
depression, giving rise to the cytokine theory of depression.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure  1  Tyrptophan–Kynurenine  pathway.  Diagram  showing  the  alteration 
of  tryptophan  metabolism  by  iFN-α.  Tryptophan  is  normally  converted  in 
5-hydroxy tryptophan (5-HTP) and serotonin (5-HT). However, this metabolism 
is switched to the KYN pathway by iDO, which is induced by immune stimuli 
such as iFN-α, and it is this pathway that produced the neurotoxin quinolinic acid 
(QUiN). Copyright © 2002, elsevier. Adapted with permission from Konsman JP,   
Parnet  P,  Dantzer  R.  Cytokine-induced  sickness  behaviour:  mechanisms  and 
implications. Trends Neurosci. 2002;25(3):154–159.
The cytokine theory of depression suggests biological 
vulnerability in certain individuals that is linked, in part, to 
the immune system.33 This could be exposed by a compound 
that stimulates the immune system (such as IFN-α), and 
increases in cytokines such as interleukin-6 (IL-6) and IL-10 
are positively correlated with depressive symptoms.40,41 The 
enhanced cytokine response seen in depressed patients reso-
nates with data that shows that people who become depressed 
during treatment are more likely to have a sustained antiviral 
response.42,43
Several potential biological mechanisms for this vulner-
ability to developing an IFN-α-induced depression have 
been examined.17,38,42,44–47 Three main mechanisms that are 
supported by clinical data are introduced briefly before 
clinical data assessing their relationship with depression is 
discussed.
Serotonin
The neurotransmitter serotonin has long been believed to play 
a role in depression;48,49 however, more recent research has 
linked the observed decrease in serotonin with a cytokine-
mediated pathway.50,51 When IFN-α is administered, it has 
been shown that there is an upregulation of the enzyme 
indoleamine 2,3-dioxygenase (IDO) that metabolizes tryp-
tophan, the precursor to serotonin.34 Thus, when IDO is 
overstimulated, there is potentially a reduction in plasma 
tryptophan and serotonin in the brain (see Figure 1),42,45,52 
which may lead to depression.51
Serotonin as a risk factor
Clinical studies in HCV patients have provided mixed results 
regarding the involvement of serotonin in the IFN-α-induced 
depression; some studies support a correlation between 
lower tryptophan levels and scores on a depression scale53 
and others do not find any correlation with tryptophan54 or 
whole blood serotonin.55 However, lower tryptophan has 
been correlated with other behavioral issues associated with 
depression such as increased irritability and aggression.56 
Reasons for differences in results could be in part explained 
by the low number of participants in the studies and also the 
issue of correlating the centrally driven disorder of depression 
with peripheral biomarkers. This issue has been addressed 
by two recent studies conducted by Raison et al.57,58 The first 
study found that when IFN-α was administered peripherally, 
there was an increase in the amount of kynurenine (KYN) 
and quinolinic acid (QUIN) centrally, which correlated with 
Montgomery–Asberg Depression Rating Scale (MADRS) 
scores. The second study found that cerebrospinal fluid (CSF) 
levels of the serotonin metabolite 5-hydroxyindoleacetic acid 
were significant predictors of depressive symptoms.57
Further support for the involvement of this system is the 
observation that depressive symptoms in this cohort are effec-
tively ameliorated by the use of SSRIs,25–28,59 implicating some 
role for serotonin in the relief of IFN-α-induced depression.
Hypothalamic–pituitary–adrenal axis
Interferons are acknowledged to activate the hypothalamic–
pituitary–adrenal (HPA) axis,60 which could in part be linked 
to the development of depression.61–63 Recent research has 
identified a pathway where stress can increase glucocorticoids 
and corticotrophin-releasing hormones, which act in tandem 
with an increase in cytokines to disrupt levels of serotonin, 
norepinephrine, and dopamine.50,64,65 Vulnerability in this 
pathway could mean a stress-related response to cytokines 
is in part responsible for IFN-induced depression.
HPA axis as a risk factor
There are mixed results for the involvement of peripheral 
biomarkers of HPA axis functioning in IFN-α-induced 
depression. One study found that IFN-α does not induce a 
change in plasma cortisol levels and cannot be correlated 
with depression scores.55 Another found that although there 
was a significant increase in daily salivary cortisol   following 
8 weeks of treatment, this change was not significantly 
  associated with depression scores.66Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure 2 Cytokine-mediated pathways that influence the CNS. Diagram showing the 
various factors that influence the CNS. There is a complex relationship, the relationship 
with monoamines and the iDO–Kyn pathway, growth factors, and stress. Stressors 
and cytokines both increase the stress response, which is reflected by an increase 
in the amount of CRH, both in the CNS and peripherally, which in turn activates 
ACTH and cortisol (CORT) levels. CRH also has a bidirectional relationship with 
serotonin (5-HT) levels, and gamma aminobutyric acid acts as a mediator for this 
process. 5-HT levels are also influenced by the production of IDO, which favors 
the production of the neurotoxin KYN over 5-HT. The stressor system and iDO–
KYN pathway both lead to a reduction in 5-HT. Cytokines also influence oxidative 
and apoptotic mechanisms, leading to a reduction in growth factors such as brain-
derived neurotrophic factor, which in turn leads to impaired neuroplastic processes 
and decreased neurogenesis, as well as cytokines having an indirect effect on growth 
factor levels; stress has also been shown to have a direct effect. The culmination of 
these three pathways can lead to the development of major depression. Copyright 
© 2005, elsevier. Adapted with permission from Hayley S, Poulter MO, Merali Z, 
Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced 
alterations of neuroplasticity. Neuroscience. 2005;135(3):659–678.
Abbreviation: CRH, corticotrophin-releasing hormone.
However, a recent study that compared HCV patients 
who were and were not taking IFN-α found that treatment 
was associated with a relative flattening of the diurnal slope 
for both salivary cortisol and adrenocorticotrophin-releasing 
hormone production and that flattening of the cortisol slope 
was associated with depressive symptoms, particularly 
somatic depressive symptoms.67 Issues leading to mixed 
results in these studies include the low number of participants 
and different measurements of cortisol (plasma cortisol and 
salivary cortisol). Another issue is the differing analyses 
employed by investigators with Raison et al67 analyzing the 
daily cortisol slope, whereas Wichers et al66 analyzed daily 
average cortisol levels.
Cytokine mechanisms
As IFN-α is a cytokine designed to affect immune system 
functioning, some researchers have chosen to look at base-
line immune system functioning and the relative increase in 
cytokines induced by treatment to see if that had any effect 
on the subsequent development of depression.
One of the main questions regarding biological risk 
factors for development of an IFN-α-induced depression is 
how the immune system, which is a peripheral system, can 
exert effects on mood and behavior via the central nervous 
system (CNS). There are two main theories regarding this 
question; the first supposes that cytokines may enter the 
brain. There are a number of ways in which cytokines may 
enter the brain. The first is via circumventricular regions 
where the blood–brain barrier (BBB) is more permeable68 
such as the organum vasculosum of the lamina terminalis, 
with uptake mechanisms for cytokines such as IL-1 being 
demonstrated at the surface of the BBB.69,70 Active transport 
mechanisms for transportation into the brain are also being 
identified for cytokines, including IL-171 and tumor necrosis 
factor-α (TNF-α).72 Another hypothesis concerns the induc-
tion of adhesion molecules such as vascular endothelial 
growth factor-1 in the brain endothelium, which increases the 
potential for circulating T-lymphocytes to cross the BBB.73
However, the second theory suggests that the immune 
system influences secondary factors that in turn interact with 
the CNS.32 In the second scenario, there is a complex interplay 
between stressors, the IDO–KYN pathway (see Figure 2), and 
factors that influence neuroplasticity in the development of 
cytokine-induced depression (see Figure 2).57,74,75
Cytokines as a risk factor
The role of cytokines in IFN-α-induced depression is a com-
plex one, with circulating cytokines, but not central cytokines, 
appearing to have a relationship with depression scores. It was 
found that a higher IL-6 response at weeks 2–4 was predictive 
of a higher MADRS score 4–6 months later.40 Another study 
found that pretreatment levels of circulating IL-6 predicted the 
incidence of developing a major depressive disorder (MDD), and 
using regression analyses, the authors were able to predict the 
following month’s Beck Depression Inventory (BDI) score using 
the previous month’s IL-6 levels.41 Other studies have also found 
that a significantly increased baseline concentration of IL-6 can 
be a predictor for subsequent depression.76 In addition to IL-6, 
other peripheral cytokines shown to correlate with an increase 
in depressive symptoms include the soluble IL-2 receptor and 
TNF-α,66 with baseline levels of soluble IL-2 receptor and IL-10 
being significantly increased in those patients who went on to 
develop depression.76 Another study that examined the relative 
importance of cytokines in depressive symptomology found that 
TNF-α and not IL-6 was correlated with mood scores.67
However, when central levels of cytokines were mea-
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the cytokines IL-6 and monocyte chemoattractant protein-1 
(MCP-1), only CSF concentrations of 5-hydroxyindoleacetic 
acid predicted depressive symptoms.57 These findings could 
mean that only peripheral cytokines can be correlated with 
depressive symptoms, possibly due to the influence of 
peripheral cytokines on the neurovegetative symptoms of 
depression.
Recent research is attempting to determine the specific 
neurobehavioral effect of cytokines by acknowledging the 
multidimensional nature of MDD as a disorder consisting 
of a number of specific subgroups of symptoms.47 There is a 
possibility that cytokines may be involved in certain aspects 
of the depressive syndrome, such as sleep and appetite 
changes, rather than being the central neurobiological cause 
of depression.35 There has been evidence that IL-6 may be 
linked in with poor sleep quality in patients taking IFN-α,41 
with poor sleep quality being identified as a predicting fac-
tor for the development of a subsequent depression.41,77
There is substantive support for the role of biological risk 
factors in the development of the IFN-α-induced depression. 
However, as results are not always conclusive and replicable, 
there is a possibility that this risk factor acts in conjuntion 
with other factors in the development of a depression.
Genetic risk factors
Biological mechanisms responsible for IFN-α-induced 
depression will inevitably be influenced by underlying genetic 
vulnerability. Several genetic polymorphisms have been asso-
ciated with an increased risk of developing depression. One 
of the most reproducible findings in this area is the observa-
tion that people who have the short allele in the functional 5´ 
promoter of the serotonin transporter gene (5-HTTLPR) are 
significantly more likely to be depressed in response to a major 
life event78,79 or in general80,81 than those people with the long 
version of this allele. Other genes implicated in depression 
are involved in the functioning of glucocorticoids,82 neuronal 
growth,83 dystonia,84 as well as the 5-HT1 A autoreceptor 
gene,85 and the IL-1β gene86 among others.87,88
These genes offer potential avenues for researchers 
looking to identify genetic risk factors to explore, and 
recent research conducted in HCV patients taking IFN has 
identified a number of genes that have been shown to cor-
relate with depression (see Table 2). The 5-HT transporter 
gene has been shown to have a role in the development of 
depression in addition to polymorphisms in the interferon 
receptor-A1 gene, the apoloprotein (APOE)  4 allele, the 
cyclooxygenase 2 (COX2) and phospholipase A2 (PLA2) 
genes, and the IL-6 gene in patients taking IFN (see Table 2). 
A number of researchers have shown that the short version of 
the 5-HTTLPR increases the risk of developing a depressive 
episode when undertaking IFN-α therapy.92,93
One recent study demonstrates the difficulty in generaliz-
ing results across different ethnic groups, with non-Hispanic 
Caucasians and Hispanic Caucasians both showing opposite 
risk polymorphisms of the 5-HTTLPR gene for depression,93 
meaning that results from different ethnic groups should be 
interpreted with caution. These studies are also limited by the 
different types of depression scales used such as the overall 
Hospital Anxiety and Depression Scale (HADS) score,91 
BDI,92–94 Zung Self-Rating Depression Scale (SDS),95 and 
BDI or SDS.89
Some genes appear to be related to a specific subgroup 
of depressive symptoms rather than the depressive disorder 
as a whole. Both the interferon receptor-A1 and PLA2 genes 
were associated primarily with somatic and neurovegetative 
symptoms.94,95 The APOE  4 allele was shown to be more so 
associated with symptoms of anger and irritability,90 with a 
recent study showing that a TNF-α polymorphism is also 
associated with labile anger and fatigue but not depression.96 
The 5-HTTLPR, IL-6, and 5-HT1A genes were associated 
with overall depression scores.89,91,92 The 5-HTTLPR gene 
was also associated with sleep quality,92 which is in itself a 
predictor of depression.41,77 Further work demonstrated that 
both the 5-HTTLPR and IL-6 genes are not associated with 
fatigue scores.92
These studies show that different genes are possibly 
involved in different aspects of the depressive disorder. There 
is also the possibility that the future may yield some useful 
genetic markers so that clinicians may identify ‘at-risk’ 
individuals and also identify what subgroups of symptoms 
patients may experience.
Demographic and social risk factors
Several demographic factors potentially impact on the devel-
opment of depression,62 including age, gender, ethnicity, and 
education level. However, there is no consensus as to whether 
any of these factors impact on the development of depression 
in patients taking IFN-α (see Table 3).
The problems with these studies are demonstrated by the 
work of Pierucci-Lagha et al93 who found that there was a 
significant difference between ethnic groups at week 12 but 
that this difference was no longer significant at week 20. This 
could mean that the observed significant difference was an 
artifact rather than a true reflection of ethnic differences in 
depression, and thus all other results regarding ethnicity must 
be interpreted with caution.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Genetic risk factors
Authors No. of participants Areas assessed Results
Bull et al89 98 Relationship between polymorphisms 
in the iL-6 and 5-HTT genes and 
symptoms of depression and fatigue 
in patients taking iFN-α
iL-6: A ‘low iL-6’ synthesizing genotype was associated with 
significantly fewer depressive symptoms during treatment
5-HTT: A ‘high transcription  
5-HTT’ genotype was associated also with fewer 
depressive symptoms
The authors propose an interaction in these genes offering 
a protective role
Gochee et al90 110 Association between APOe 
genotypes and neuropsychiatric 
symptoms in patients taking iFN-α
APOe ´ ε4 allele: More likely to be referred to a psychiatrist 
and had more neuropsychiatric symptoms (more likely 
to experience irritability, anger, and mood disturbances). 
in addition, more likely to experience a neuropsychiatric 
event sooner
Depression carrier 10 (38.5%), noncarrier 29 (34.5%), 
irritability 15/17 (57.7%/20.2%), anxiety/other mood 15/18 
(57.7%/21.4%) prior psychiatric 9/15 (34.6%/17.9%)
However, this gene and a previous history of psychiatric 
illness was not significant
Kraus et al91 139 investigate the impact of genetic 
variations within the serotonin 
system on likelihood of depression 
development during treatment
5-HT1A receptor gene HTR1A variation: Those patients 
homozygous for this gene were significantly more likely to 
develop depression during treatment and have significantly 
higher HADS scores when compared to patients who 
carried 5-HTT or TPH2 polymorphisms
Lotrich et al92 71 Influence of the serotonin 
transporter gene in development of 
depression in patients taking iFN-α
5-HTTLPR: Those patients with the LA -allele were less 
likely to develop depression, whereas those patients who 
displayed the S/S allele of this gene the most vulnerable to 
developing depression. This increased rate of depression 
in vulnerable patients was reported to be related to poor 
sleep quality in carriers of the S/S allele
Pierucci-Lagha et al93 1015 Assess the influence of a 
polymorphism in the serotonin 
transporter gene on subsequent 
depression development
5-HTTLPR: 5-HTLLPR genotype moderated the 
occurrence of depression in non-Hispanic Caucasians and 
Hispanic Caucasians but not African-Americans
in non-Hispanic Caucasians, the L’ allele was associated 
with depression scores, whereas in Hispanic Caucasians, 
the S’-allele was associated with depression scores
in both these populations, the 5-HTTLPR genotype 
interacted with psychiatric history and time to produce 
higher depression scale scores
Su et al94 132 Ascertain the influence of 
polymorphisms in genes that regulate 
the metabolism of polyunsaturated 
fatty acids (PLA2 and COX2)
COX2 rs4648308 and PLA2 Banl GG genotypes: Those 
patients who had the COX2 rs4648308 allele were 
significantly more likely to develop a depression. The PLA2 
Banl polymorphism was associated with a higher severity of 
the somatic symptoms of depression
Yoshida et al95 50 Development of depression in 
HCv patients taking iFNα and 
how this relates to four promoter 
polymorphisms of the iFNAR1 gene
GT promoter repeat dinucleotide microsatellite 
polymorphism of the iFNAR1 gene: Patients with the 
5/14 genotype of the GT repeat dinucleotide microsatellite 
polymorphism showed greater differences in the baseline 
to maximum difference in the SDS index score of 
neurovegetative/somatic symptoms (P = 0.0084)
Notes: Studies that examine the impact of genetic risk factors on the development of depression during treatment with iFN-α.
The only social risk factor that appears to influence 
levels of depression is that of social support, with lower 
levels leading to a significantly higher risk of develop-
ing a depression.24 Support for the involvement of this 
demographic factor also comes from research conducted 
in patients with malignant melanoma, where patients who 
employed effective coping strategies and had social support 
were less likely to become depressed.105 However, more 
work needs to be conducted in this area before any concrete 
conclusions can be drawn.
Treatment-related risk factors
Higher doses of IFN-α are associated with more numer-
ous side effects.106,107 However, it is not clear whether this Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Demographic risk factors
Risk factor Evidence for Evidence against
Age Castera et al97
Patients who developed mood disorders during treatment were 
significantly younger (mean age 43) than those who did not (mean age 48)
Horikawa et al98  
Only risk factor in their study where 23.2% of patients developed 
depression was advanced age
evon et al24
Patients who developed a depression were significantly younger than 
those who did not
Hauser et al99
Of the 33% of their patients who became 
depressed, there was no difference in age to those 
who did not become depressed
Miyaoka et al100
Martin-Santos et al101
Raison et al62
Su et al94
education level Martin-Santos et al101
Those people with only a primary education level (ie, lower levels  
of education) were significantly more likely to develop a depressive  
or anxiety disorder
Su et al94
Gender Gohier et al102
Sixty-four percent of women developed a depression on treatment
Su et al94
Significantly more women (52.4%) than men (23.8%) developed  
a depression on treatment
Bonaccorso et al103
Castera et al97
Hauser et al99
Lotrich et al104
Miyaoka et al100
Martin-Santos et al101
Raison et al62
ethnicity Hauser et al99
The only demographic baseline characteristic that yielded a significant 
difference was that there were significantly more Caucasians (76.9%) 
who developed depression than African-Americans (23.1%)
Martin-Santos et al101
Significantly more people who developed a depressive or anxiety 
disorder on treatment were immigrants (64%) compared with 
nonimmigrants (37%)
Pierucci-Lagha et al93
At 12 weeks, non-Hispanic Caucasians had a significantly higher 
level of depression (39%) than African-Americans (29%) or Hispanic 
Caucasians (28%). However, this significant difference disappeared at 
20 weeks
evon et al24  
There was no significant difference in the 
development of depression between those 
patients who were Caucasian and those who were 
African-American
Social support evon et al24
Those patients who reported having lower levels of social support 
were significantly more likely to develop depression than those who 
had such support
–
Notes: Studies where impact of demographic risk factors was investigated with relation to depression occurrence during iFN-α treatment.
observed dose effect also holds for the development of 
depression (see Table 4). In general, rates of depression in 
patients taking IFN-α for HCV vary from 0%109,118 to up to 
50%.21,62,97,99–101,104,108,113,116 Oncology patients taking up to 
five times the dose of IFN-α than those patients infected 
with HCV are prescribed have similar rates of depression 
from 5%119 up to 50%.120 Given that the doses of IFN-α 
given to the two populations are very different, there does 
not appear to be a convincing difference regarding the impact 
of dose on development of depression. However, a potential 
confounding factor is the retrospective design of most of 
these studies. This design can yield lower rates of depres-
sion than prospective depression-specific design, used by 
many contemporary researcher-led studies,62 perhaps also 
explaining the lower rates of depression seen in some of the 
studies in Table 4.107
Other treatment-related factors such as coprescription 
of ribavirin and length of treatment do not seem to yield a 
general consensus on the impact of treatment-related risk 
factors on depression. This suggests that while treatment 
factors impact on the ‘sickness’ aspect of sickness behavior, 
that is, those somatic complaints that follow an infection or 
illness (see Table 1), there is little evidence suggesting that 
they impact hugely on the behavioral aspects of sickness 
behavior, one of which is depression.
Psychobehavioral risk factors
Risk factors implicating both psychological and behavioral 
vulnerabilities as being predictors of subsequent depres-
sion have been arguably the most researched in this field 
as simple reasoning would suggest that if a drug induces 
psychobehavioral side effects, a pre-existing vulnerability Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 4 Studies reviewed to assess whether treatment-related risk factors can be associated with development of depression in 
patients prescribed iFN-α
Risk factor Evidence for Evidence against
Dose of interferon Fried et al108
Of those patients taking 180 µg PeG–iFN, 20%–22% became 
depressed; however, 30% of those patients taking 3 MU of 
iFN-α b became depressed. (However, this was not reported 
to be significant).
Mulder et al109
Ascribe the fact that they found no significant changes in 
depressive symptamology to lower doses of interferon used
Renault et al110
Those patients taking a higher dose of iFN-α (10 MU every 
other day) were more likely to develop what the authors 
termed an ‘affective syndrome’ than those patients taking 5 
MU every day
Malaguarnera et al111
when different types of interferon were compared, 
mean scores on SDS were higher in those patients taking 
recombinant interferon-α-2a or lymphoblastoid interferon-α 
than recombinant interferon-α-2b or leukocyte interferon-α
Horikawa et al98
No evidence that type and dose of interferon impacted  
on depression rates
iino112
in patients taking three regimens of high-dose iFN 
treatment (10 MU over varying periods up to 14 weeks  
to a total of 480 MU). Rates of reported depression ranged 
from 4.8% to 7.1%
Kraus et al113
There was no significant difference in reported rates of 
depression between those patients taking 5 MU iFN-α 
(33.3%) and those taking 80–150 µg PeG–iFN-α (40%)
Manns et al114
in a comparison of different dosing regimes of interferon, 
there was no significant difference in rates of depression 
between higher dose peginterefron plus ribavirin (31%), 
lower dose peginterefron + ribavirin (29%), and interferon 
plus ribavirin (34%)
Okanoue et al107
in a clinical study where patients were taking 6–10 MU of 
interferon, only 3.5% became clinically depressed
Zeuzem et al115
There was no significant difference in reported rates of 
depression between those patients taking 180 µg/week of 
PeG–iFN-α (16%) and those patients taking 3 MU iFN-α 
(23%). Clinically depressed
Length of treatment – Castera et al97
There was no significant difference in rates of depression 
between those on treatment for 24 weeks (53%) and those 
on treatment for 48 weeks (47%)
Hauser et al99
Median time to depression in those patients who 
developed it was 12 weeks
Horikawa et al98
73.9% of patients developed depression within first  
8 weeks
Robaeys et al116
Depression occurred in patients between 4 and 26 weeks, 
with the mean time to depression 10 weeks
Retreatment following 
nonresponse
– Quarantini et al117
in nonresponder patients, rates of iFN-α-induced 
depression were comparable to studies in treatment naive 
patients with 10% of 30 patients being diagnosed with 
depression during treatment
Ribavirin Raison et al62
Patients who received weight-based dosing of ribavirin 
(800–1400 µg/day) were significantly more likely to develop 
moderate to severe depressive symptoms than those people 
who received a standard dose (800 µg/day)
Davis et al12
No significant difference between development of 
depression in those patients taking iFN (11%) and those 
patients taking iFN + ribavirin (16%)
Fried et al108
No difference in rates of depression between two groups 
both receiving PeG–iFN-α with either ribavirin (22%) or 
Placebo (20%)
McHutchison et al21
There were no significant differences between the rates 
of depression in those people taking a standard dose of 
iFN (25%–37%) and those patients taking interferon and 
ribavirin (32%–36%)Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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to developing a psychiatric disorder (be that history, current 
diagnosis, behavioral problems, or higher than normal rat-
ing on a psychiatric scale) should lead such patients to be 
more ‘at risk’ than others. Following an early observation 
that higher pretreatment scores on a depressive rating scale 
led to cancer patients having a higher risk of becoming 
depressed,121 several studies on HCV patients have explored 
this observation in more detail, with an emerging consensus 
that this risk factor results in patients being significantly 
more likely to develop depression when taking IFN-α (see 
Table 5). It could, however, also be argued that this ‘risk fac-
tor’ has the most support simply because it has been the most 
investigated. This risk factor goes hand in hand with findings 
which suggest that people with a past history of psychiatric 
illness, in particular MDD, are more vulnerable to becom-
ing depressed on treatment.62,97 The research summarized in 
Table 5 suggests that some kind of ‘subsyndromal’ depres-
sion could leave people more susceptible to developing an 
IFN-α-induced depression.
It has been shown that those people who become 
depressed on treatment are more likely to have an increased 
baseline score on a depression scale (see Table 5). Raison 
et al127 propose that all people prescribed IFN-α develop a 
side effect profile, comprised of neurovegetative symptoms 
(those somatic aspects of sickness behavior) or depressive-
specific symptoms (those symptoms specific to the behav-
ioral parts of sickness behavior). Both of these side effect 
profiles are measured by depression rating scales. Thus, if 
a person scores highly at baseline on one of these scales, 
it would stand to reason that these scores would remain 
throughout the course of the treatment and that some addi-
tional treatment-related factors would also come into play. 
The additive effect would mean that this subset of patients 
would be more at risk of being diagnosed with a depressive 
disorder due to elevated scores on a depression rating scale. 
Should this be the case, then all patients would experience 
an increase in scores on a depression rating scale relative to 
time, which is something that much of the literature seems 
to support.23,25,104,108,111,113,114,125,128–134 In fact, some researchers 
have pinpointed a relative increase in somatic components 
of depressive rating scales as being primarily responsible 
for the increase in scores seen in many patients.46 However, 
many recent studies have become aware of the potential con-
founds associated with using only depression rating scales; 
the range cannot be deleted and so diagnose MDD using 
DSM-IV-TR criteria. In order to meet criteria for diagnosis 
of MDD, patients are required to show depressed mood for 
most of the days, nearly every day, and/or demonstrate a 
direct loss in interest in activities every day for 2 weeks. 
Neither of these factors are somatic in nature, although it 
could be said that they may result from a primarily somatic 
complaint.
Psychiatric morbidity at baseline is perhaps the most 
intriguing of all research in this area. Evidence, however, is 
varied with some studies finding no difference in develop-
ment of depression in patients taking IFN-α, regardless of 
psychiatric history, and some indicating that patients are more 
likely to develop depression should they exhibit psychiatric 
vulnerability (see Table 5). This in part could be related to 
the fact that many of the studies that investigate a predefined 
‘at-risk’ population such as those who have pre-existing psy-
chiatric disorder are often coprescribed additional support at 
baseline with SSRIs and therapy.29–31
Another important issue with this population is whether 
researchers are investigating the incidence of total depression 
or ‘new’ depression only. Hauser et al99 reported an incidence 
of 6% of ‘new’ depression in the psychiatric group, which 
was not significant when compared against the incidence of 
‘new’ depression in the other groups examined. However, 
if people depressed prior to treatment were included, then 
the total incidence of depression in this group was 44%, a 
much higher rate than in other groups. Some studies that 
have found evidence for a past psychiatric history impact-
ing on IFN-α-induced depression include people who were 
diagnosed as being depressed prior to the start of treatment 
(see Table 5). This begs the question of which approach is 
better. If examining a ‘psychiatric group’, then a substantial 
proportion of this group may have depression, and removing 
this group from subsequent analyses will impact upon the 
level of depression observed. At the same time, however, 
these studies are supposedly examining IFN-α-induced 
depression, and if a person is depressed when commenc-
ing treatment, the depression observed while on treatment 
is not an IFN-α-induced phenomenon and should not be 
included.
The approach adopted by Hauser et al99 is perhaps the 
most sensible, given this dilemma. They report their results 
in terms of ‘new depression’ but also mention that those 
depressed prior to treatment were more likely to develop 
moderate or severe depression compared to patients in other 
groups, thus providing evidence that IFN-α may increase 
depressive symptoms relative to the baseline that people 
begin treatment at. Thus, people with a lower ‘baseline 
depression’ will have an increase in depressive symptoms, 
but this is not always necessarily enough of an increase to 
mean a diagnosis of depression. However, those people with Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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a
 
h
i
s
t
o
r
y
 
o
f
 
M
D
D
 
w
a
s
 
a
 
s
i
g
n
i
fi
c
a
n
t
 
p
r
e
d
i
c
t
o
r
 
o
f
 
m
o
d
e
r
a
t
e
 
o
r
 
s
e
v
e
r
e
 
d
e
p
r
e
s
s
i
o
n
C
a
s
t
e
r
a
 
e
t
 
a
l
1
2
4
N
o
n
e
 
o
f
 
t
h
e
 
1
2
%
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
d
e
v
e
l
o
p
e
d
 
a
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
h
a
d
 
a
 
p
s
y
c
h
i
a
t
r
i
c
 
h
i
s
t
o
r
y
D
i
e
p
e
r
i
n
k
 
e
t
 
a
l
1
2
5
O
f
 
t
h
o
s
e
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
i
n
g
 
p
s
y
c
h
i
a
t
r
i
c
 
c
a
r
e
 
a
t
 
b
a
s
e
l
i
n
e
,
 
4
5
%
 
m
e
t
 
c
r
i
t
e
r
i
a
 
f
o
r
 
M
D
D
,
 
w
h
i
c
h
 
r
o
s
e
 
t
o
 
5
6
%
 
(
1
1
%
 
i
n
c
i
d
e
n
c
e
 
o
f
 
n
e
w
 
d
e
p
r
e
s
s
i
o
n
)
;
 
h
o
w
e
v
e
r
,
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
s
 
n
o
t
 
r
e
c
e
i
v
i
n
g
 
p
s
y
c
h
i
a
t
r
i
c
 
c
a
r
e
 
a
t
 
b
a
s
e
l
i
n
e
,
 
t
h
e
r
e
 
w
a
s
 
a
 
2
3
%
 
i
n
c
r
e
a
s
e
 
i
n
 
n
e
w
 
d
e
p
r
e
s
s
i
o
n
 
d
u
r
i
n
g
 
t
r
e
a
t
m
e
n
t
H
o
w
e
v
e
r
,
 
d
e
s
p
i
t
e
 
t
h
i
s
,
 
a
 
h
i
s
t
o
r
y
 
o
f
 
t
w
o
 
o
r
 
m
o
r
e
 
p
s
y
c
h
i
a
t
r
i
c
 
d
i
a
g
n
o
s
e
s
 
w
a
s
 
i
d
e
n
t
i
fi
e
d
 
a
s
 
a
 
r
i
s
k
 
f
a
c
t
o
r
 
f
o
r
 
h
a
v
i
n
g
 
t
o
 
s
t
a
r
t
 
a
n
t
i
d
e
p
r
e
s
s
a
n
t
 
t
r
e
a
t
m
e
n
t
 
d
u
r
i
n
g
 
i
F
N
,
 
d
e
s
p
i
t
e
 
n
o
t
 
b
e
i
n
g
 
s
i
g
n
i
fi
c
a
n
t
 
(
P
 
,
 
0
.
0
8
)
,
 
a
s
 
w
e
l
l
 
a
s
 
a
 
f
a
m
i
l
y
 
h
i
s
t
o
r
y
 
o
f
 
m
o
o
d
 
d
i
s
o
r
d
e
r
s
,
 
w
h
i
c
h
 
w
a
s
 
s
i
g
n
i
fi
c
a
n
t
.
 
Y
e
t
 
n
o
n
e
 
o
f
 
t
h
e
s
e
 
f
a
c
t
o
r
s
 
w
e
r
e
 
i
d
e
n
t
i
fi
e
d
 
a
s
 
b
e
i
n
g
 
i
m
p
o
r
t
a
n
t
 
f
o
r
 
t
h
e
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
H
o
r
i
k
a
w
a
 
e
t
 
a
l
9
8
 
 
N
o
 
e
v
i
d
e
n
c
e
 
f
o
r
 
p
r
i
o
r
 
h
i
s
t
o
r
y
 
o
f
 
p
s
y
c
h
i
a
t
r
i
c
 
d
i
s
o
r
d
e
r
s
 
w
a
s
 
a
 
r
i
s
k
 
f
a
c
t
o
r
 
H
a
u
s
e
r
 
e
t
 
a
l
9
9
 
 
N
o
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
p
a
s
t
 
p
s
y
c
h
i
a
t
r
i
c
 
h
i
s
t
o
r
y
 
b
e
t
w
e
e
n
 
t
h
o
s
e
 
w
h
o
 
d
i
d
 
a
n
d
 
d
i
d
 
n
o
t
 
b
e
c
o
m
e
 
d
e
p
r
e
s
s
e
d
L
o
t
r
i
c
h
 
e
t
 
a
l
1
0
4
 
O
f
 
t
h
e
 
9
 
(
3
9
%
)
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
d
e
v
e
l
o
p
e
d
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
o
n
,
 
o
n
l
y
 
3
 
o
f
 
t
h
e
s
e
 
(
3
3
%
)
 
h
a
d
 
a
 
p
a
s
t
 
h
i
s
t
o
r
y
 
o
f
 
a
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
e
p
i
s
o
d
e
,
 
w
h
e
r
e
a
s
 
3
6
%
 
o
f
 
t
h
e
 
g
r
o
u
p
 
t
h
a
t
 
d
i
d
 
n
o
t
 
b
e
c
o
m
e
 
d
e
p
r
e
s
s
e
d
 
a
l
s
o
 
h
a
d
 
a
 
h
i
s
t
o
r
y
 
o
f
 
p
s
y
c
h
i
a
t
r
i
c
 
i
l
l
n
e
s
s
M
a
r
t
i
n
-
S
a
n
t
o
s
 
e
t
 
a
l
1
0
1
A
 
p
a
s
t
 
h
i
s
t
o
r
y
 
o
f
 
d
e
p
r
e
s
s
i
v
e
 
o
r
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
s
 
d
i
d
 
n
o
t
 
i
m
p
a
c
t
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
o
n
 
t
h
e
 
l
i
k
e
l
i
h
o
o
d
 
t
o
 
d
e
v
e
l
o
p
 
a
 
n
e
w
 
d
e
p
r
e
s
s
i
o
n
.
 
(
P
a
t
i
e
n
t
s
 
w
i
t
h
 
d
e
p
r
e
s
s
i
o
n
 
a
t
 
b
a
s
e
l
i
n
e
 
w
e
r
e
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
t
h
i
s
 
a
n
a
l
y
s
i
s
.
)
M
u
l
d
e
r
 
e
t
 
a
l
1
0
9
D
e
s
p
i
t
e
 
t
h
e
 
f
a
c
t
 
t
h
a
t
 
h
a
v
i
n
g
 
h
a
d
 
a
 
l
i
f
e
t
i
m
e
 
h
i
s
t
o
r
y
 
o
f
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
o
n
 
m
e
a
n
t
 
h
i
g
h
e
r
 
m
e
a
n
 
d
e
p
r
e
s
s
i
o
n
 
s
c
o
r
e
s
 
t
h
r
o
u
g
h
o
u
t
 
t
r
e
a
t
m
e
n
t
,
 
t
h
i
s
 
d
i
d
 
n
o
t
 
p
r
e
d
i
c
t
 
t
h
e
 
o
n
s
e
t
 
o
r
 
w
o
r
s
e
n
i
n
g
 
o
f
 
t
h
e
s
e
 
s
y
m
p
t
o
m
s
P
a
r
i
a
n
t
e
 
e
t
 
a
l
3
1
P
a
t
i
e
n
t
s
 
w
i
t
h
 
a
 
p
r
e
-
e
x
i
s
t
i
n
g
 
p
s
y
c
h
i
a
t
r
i
c
 
d
i
s
o
r
d
e
r
 
w
e
r
e
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
d
e
v
e
l
o
p
 
p
s
y
c
h
i
a
t
r
i
c
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
 
(
2
4
%
)
 
w
h
e
n
 
c
o
m
p
a
r
e
d
 
t
o
 
c
a
s
e
 
c
o
n
t
r
o
l
s
 
(
1
9
%
)
P
s
y
c
h
i
a
t
r
i
c
 
h
i
s
t
o
r
y
R
e
n
a
u
l
t
 
e
t
 
a
l
1
1
0
T
h
o
s
e
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
a
 
p
a
s
t
 
h
i
s
t
o
r
y
 
o
f
 
a
n
 
a
f
f
e
c
t
i
v
e
 
d
i
s
o
r
d
e
r
 
w
e
r
e
 
n
o
t
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
d
e
v
e
l
o
p
 
a
n
 
‘
a
f
f
e
c
t
i
v
e
 
s
y
n
d
r
o
m
e
’
,
 
a
s
 
5
7
%
 
o
f
 
p
e
o
p
l
e
 
w
h
o
 
d
e
v
e
l
o
p
e
d
 
d
e
p
r
e
s
s
i
o
n
 
h
a
d
 
t
h
i
s
 
h
i
s
t
o
r
y
,
 
w
h
e
r
e
a
s
 
4
7
%
 
o
f
 
p
e
o
p
l
e
 
w
h
o
 
d
i
d
 
n
o
t
 
d
e
v
e
l
o
p
 
a
n
y
 
p
s
y
c
h
i
a
t
r
i
c
 
s
i
d
e
 
e
f
f
e
c
t
s
 
a
l
s
o
 
h
a
d
 
S
c
h
a
e
f
e
r
 
e
t
 
a
l
3
0
M
o
r
e
 
p
s
y
c
h
i
a
t
r
i
c
 
p
a
t
i
e
n
t
s
 
h
a
d
 
a
 
h
i
g
h
e
r
 
b
a
s
e
l
i
n
e
 
d
e
p
r
e
s
s
i
o
n
;
 
h
o
w
e
v
e
r
,
 
t
h
e
r
e
 
w
a
s
 
n
o
 
s
i
g
n
i
fi
c
a
n
t
 
i
n
c
r
e
a
s
e
 
i
n
 
d
e
p
r
e
s
s
i
o
n
 
i
n
 
t
h
e
 
p
s
y
c
h
i
a
t
r
i
c
 
g
r
o
u
p
 
(
6
%
)
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
t
h
e
 
m
e
t
h
a
d
o
n
e
 
g
r
o
u
p
 
(
1
4
%
)
,
 
f
o
r
m
e
r
 
a
d
d
i
c
t
i
o
n
 
g
r
o
u
p
 
(
2
9
%
)
,
 
a
n
d
 
t
h
e
 
c
o
n
t
r
o
l
 
g
r
o
u
p
 
(
1
2
%
)
 
i
n
 
t
h
e
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
a
 
n
e
w
 
d
e
p
r
e
s
s
i
o
n
.
 
i
n
 
t
o
t
a
l
,
 
1
6
%
 
o
f
 
a
l
l
 
p
a
t
i
e
n
t
s
 
d
e
v
e
l
o
p
e
d
 
a
 
n
e
w
 
d
e
p
r
e
s
s
i
o
n
H
o
w
e
v
e
r
,
 
t
h
o
s
e
 
p
a
t
i
e
n
t
s
 
w
h
o
 
w
e
r
e
 
i
n
 
t
h
e
 
p
s
y
c
h
i
a
t
r
i
c
 
g
r
o
u
p
 
w
e
r
e
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
d
e
v
e
l
o
p
 
s
e
v
e
r
e
 
d
e
p
r
e
s
s
i
v
e
 
s
i
d
e
 
e
f
f
e
c
t
s
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
5
 
(
C
o
n
t
i
n
u
e
d
)
R
i
s
k
 
f
a
c
t
o
r
E
v
i
d
e
n
c
e
 
f
o
r
E
v
i
d
e
n
c
e
 
a
g
a
i
n
s
t
S
l
e
e
p
F
r
a
n
z
e
n
 
e
t
 
a
l
7
7
O
f
 
t
h
e
 
1
9
%
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
d
e
v
e
l
o
p
e
d
 
M
D
D
,
 
w
h
e
n
 
o
t
h
e
r
 
f
a
c
t
o
r
s
 
w
e
r
e
 
c
o
n
t
r
o
l
l
e
d
 
f
o
r
,
 
p
o
o
r
 
s
l
e
e
p
 
q
u
a
l
i
t
y
 
p
r
i
o
r
 
t
o
 
t
r
e
a
t
m
e
n
t
 
w
a
s
 
a
 
p
r
e
d
i
c
t
o
r
 
 
o
f
 
s
h
o
r
t
e
r
 
t
i
m
e
 
t
o
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
o
n
G
o
h
i
e
r
 
e
t
 
a
l
1
0
2
e
i
g
h
t
y
-
t
w
o
 
p
e
r
c
e
n
t
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
p
r
e
s
e
n
t
e
d
 
w
i
t
h
 
s
l
e
e
p
 
d
i
s
o
r
d
e
r
s
 
d
u
r
i
n
g
 
t
r
e
a
t
m
e
n
t
 
a
l
s
o
 
s
h
o
w
e
d
 
a
n
x
i
o
d
e
p
r
e
s
s
i
v
e
 
s
y
m
p
t
o
m
s
,
 
w
i
t
h
 
s
l
e
e
p
 
d
i
s
t
u
r
b
a
n
c
e
 
a
l
s
o
 
b
e
i
n
g
 
a
 
p
r
e
d
i
c
t
o
r
 
o
f
 
s
u
i
c
i
d
a
l
 
i
d
e
a
t
i
o
n
P
r
a
t
h
e
r
 
e
t
 
a
l
4
1
P
o
o
r
 
s
l
e
e
p
 
q
u
a
l
i
t
y
 
w
a
s
 
a
 
p
r
e
d
i
c
t
o
r
 
o
f
 
t
h
e
 
n
e
x
t
 
m
o
n
t
h
’
s
 
B
D
i
 
s
c
o
r
e
s
–
S
u
b
s
t
a
n
c
e
 
a
b
u
s
e
C
a
s
t
e
r
a
 
e
t
 
a
l
9
7
F
o
r
t
y
-
fi
v
e
 
p
e
r
c
e
n
t
 
o
f
 
t
h
o
s
e
 
p
a
t
i
e
n
t
s
 
t
h
a
t
 
b
e
c
a
m
e
 
d
e
p
r
e
s
s
e
d
 
h
a
d
 
a
 
h
i
s
t
o
r
y
 
 
o
f
 
i
v
 
d
r
u
g
 
u
s
e
,
 
o
n
l
y
 
1
5
%
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
s
 
w
h
o
 
d
i
d
 
n
o
t
 
b
e
c
o
m
e
 
d
e
p
r
e
s
s
e
d
 
w
e
r
e
 
f
r
o
m
 
t
h
i
s
 
s
a
m
e
 
p
o
p
u
l
a
t
i
o
n
S
c
h
a
e
f
e
r
 
e
t
 
a
l
3
0
F
o
r
t
y
-
t
h
r
e
e
 
p
e
r
c
e
n
t
 
o
f
 
p
a
t
i
e
n
t
s
 
w
h
o
 
d
r
o
p
p
e
d
 
o
u
t
 
o
f
 
s
t
u
d
y
 
h
a
d
 
f
o
r
m
e
r
 
d
r
u
g
 
a
d
d
i
c
t
i
o
n
 
(
c
o
m
p
a
r
e
d
 
w
i
t
h
 
1
8
%
 
i
n
 
p
s
y
c
h
i
a
t
r
i
c
 
g
r
o
u
p
,
 
1
4
%
 
m
e
t
h
a
d
o
n
e
 
g
r
o
u
p
,
 
a
n
d
 
1
3
%
 
c
o
n
t
r
o
l
 
g
r
o
u
p
)
.
 
T
h
e
s
e
 
p
a
t
i
e
n
t
s
 
a
l
s
o
 
t
e
n
d
e
d
 
t
o
 
h
a
v
e
 
m
o
r
e
 
o
f
t
e
n
,
 
b
u
t
 
m
i
l
d
e
r
 
e
p
i
s
o
d
e
s
 
o
f
 
d
e
p
r
e
s
s
i
o
n
H
a
u
s
e
r
 
e
t
 
a
l
9
9
M
a
r
t
i
n
-
S
a
n
t
o
s
 
e
t
 
a
l
1
0
1
i
n
 
t
h
i
s
 
s
t
u
d
y
,
 
a
 
p
a
s
t
 
h
i
s
t
o
r
y
 
o
f
 
a
l
c
o
h
o
l
 
o
r
 
o
p
i
o
i
d
 
d
e
p
e
n
d
e
n
c
e
 
d
i
d
 
n
o
t
 
m
a
k
e
 
p
e
o
p
l
e
 
m
o
r
e
 
l
i
k
e
l
y
 
t
o
 
d
e
v
e
l
o
p
 
d
e
p
r
e
s
s
i
o
n
R
a
i
s
o
n
 
e
t
 
a
l
6
2
N
o
 
e
v
i
d
e
n
c
e
 
t
h
a
t
 
p
a
s
t
 
s
u
b
s
t
a
n
c
e
 
u
s
e
 
i
m
p
a
c
t
s
 
o
n
 
r
a
t
e
s
 
o
f
 
d
e
p
r
e
s
s
i
o
n
R
e
n
a
u
l
t
 
e
t
 
a
l
1
1
0
N
o
n
e
 
o
f
 
t
h
e
 
p
a
t
i
e
n
t
s
 
i
n
 
t
h
e
 
d
r
u
g
 
a
b
u
s
e
 
g
r
o
u
p
 
d
e
v
e
l
o
p
e
d
 
t
h
e
 
‘
a
f
f
e
c
t
i
v
e
 
s
y
n
d
r
o
m
e
’
,
 
a
l
t
h
o
u
g
h
 
6
7
%
 
o
f
 
t
h
e
m
 
d
e
v
e
l
o
p
e
d
 
d
e
l
i
r
i
u
m
N
o
t
e
s
:
 
S
t
u
d
i
e
s
 
i
n
v
e
s
t
i
g
a
t
i
n
g
 
t
h
e
 
r
o
l
e
 
o
f
 
p
s
y
c
h
i
a
t
r
i
c
 
r
i
s
k
 
f
a
c
t
o
r
s
 
o
n
 
t
h
e
 
d
e
v
e
l
o
p
m
e
n
t
 
o
f
 
d
e
p
r
e
s
s
i
o
n
 
d
u
r
i
n
g
 
i
F
N
-
α
 
t
r
e
a
t
m
e
n
t
 
f
o
r
 
H
C
v
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
S
T
A
i
-
Y
,
 
S
t
a
t
e
-
T
r
a
i
t
 
A
n
x
i
e
t
y
 
i
n
v
e
n
t
o
r
y
;
 
M
A
D
R
S
,
 
M
o
n
t
g
o
m
e
r
y
–
A
s
b
e
r
g
 
D
e
p
r
e
s
s
i
o
n
 
R
a
t
i
n
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higher depression scores when commencing treatment will 
have the same kind of increase in depressive symptoms lead-
ing, in their case, to a diagnosis of depression.
Another risk factor that has increasing support is personal-
ity, with those individuals who have low self-directedness122 and 
high neuroticism92,104 being more likely to become depressed on 
treatment. The likelihood is that these personality factors inter-
act with other psychobehavioral risk factors; however, more 
research needs to be conducted in order to determine this.
A behavioral risk factor that is gaining increasing inter-
est from researchers is the impact of sleep disorders on the 
subsequent development of depression. Studies have shown 
that those patients who exhibit higher scores on the Pittsburgh 
Sleep Quality Index at baseline are more likely to develop 
MDD in a shorter time span,77 with sleep disturbance on 
treatment being a predictive factor for subsequent depression 
scale scores41 and suicidal ideation.102 However, a recent 
literature review on sleep disturbance in HCV states that the 
presence of insomnia in this cohort is influenced by underly-
ing psychiatric comorbidity such as depression.122 This could 
mean that sleep disturbance interacts with other risk factors 
in determining the possible risk of developing depression 
in individuals. This idea is supported by Lotrich et al92 who 
found that when assessed alone, baseline sleep quality and 
BDI could predict depression; however, when Pittsburgh 
Sleep Quality Index and BDI scores were combined with 
5-HTTLPR genotype, the effect of sleep and depression scale 
scores were diminished and only genotype had a significant 
impact on the development of depression.
The area of psychobehavioral risk factors impacting on 
subsequent development of IFN-α-induced depression is per-
haps the most convincing in terms of evidence gathered and 
rationale supplied by researchers. This risk factor is inevita-
bly influenced by genetic and/or biological vulnerabilities.
Limitations
Limitations of cited studies
Many of the studies examined are retrospective and have 
only identified ‘risk factors’ following patients’ completion 
of treatment. It could, therefore, be argued that it is easy 
to   retrospectively identify a risk factor using statistics to 
compare ‘depressed’ and ‘nondepressed’ groups. In fact, a 
prospective depression-specific design rather than the ret-
rospective general design often employed in clinical trials 
generally yields much higher rates of depression.135 Despite 
this, a risk factor might only be identified using a prospec-
tive depression-specific design, and following identification 
of that risk factor, other studies could have the effect of that Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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particular risk factor on the development of depression as 
their primary hypothesis. This has certainly been the case 
with many studies on psychiatric side effects, and this area 
of research has much stronger empirical evidence support-
ing it than others (eg, demographic risk factors, which when 
examined in a study, appears to be an afterthought examined 
only retrospectively). Paradoxically, many studies have 
focused from the outset on the side effect of depression and 
will often find higher rates of depression, as they are ‘on 
the look out’ for this specific side effect. Studies of general 
side effects rather than the specific side effect of depression 
have found lower rates of depression. It may be the same 
with other risk factors. Should researchers and clinicians 
be more aware that certain risk factors could lead to an 
increased likelihood of depression being developed, depres-
sion in these individuals may be diagnosed more quickly. 
Many of these studies employ scales to examine depressive 
symptoms, and these scales are often high in somatic items, 
which because of IFN-α being a drug that induces a ‘sick-
ness behavior’, many patients taking this drug will score 
highly on these items simply because they are sick, rather 
than being depressed per se.46 It will be important in future 
studies to determine the subscale loads of those items that 
are somatic or affective.
When assessing the role of the various biological and 
genetic risk factors identified in this review, there are some 
key issues that limit the interpretation of results. Many of 
the biological risk factors identified were not readily identifi-
able at baseline and instead are correlated with depressive 
symptoms after the induction of therapy. Another issue is the 
problem of correlating mood scores with a biomarker; high 
scores on a depression scale are not neccesarily representa-
tive of a depressive disorder and could instead be linked in 
to higher somatic symptoms. Some studies have shown that 
their biomarker of interest is preferentially correlated with 
somatic symptoms,67,94,95 and future work should determine 
which cluster of symptoms each biomarker is associated with. 
The majority of studies examined in this review chose to 
conduct correlational and regression analysis, with no   studies 
comparing between groups who did and did not develop 
a depression. In future, it would be interesting to conduct 
analyses that include all comparisons in order to gain a full 
appreciation of the role of biomarkers in   IFN-α-induced 
depression.
Moreover, in issues relating to experimental design, there 
is the simple, yet often ignored issue that many patients 
who have HCV are more depressed than a healthy popula-
tion; in fact, rates of depression in HCV patients can be as 
high as 40%.136 Yates and Gleason137 found that in a study 
of 78 patients who were HCV positive, the main reasons for 
being referred for psychiatric consultation were showing 
psychiatric symptoms, consultations either prior to listing for 
liver transplantation and/or therapy with IFN-α, and that the 
lowest number of patients that were referred for treatment 
in this group were those patients receiving IFN-α who had 
developed depressive symptoms. Furthermore, populations 
acquiring HCV tend to be from backgrounds that can lead 
them to have a higher level of depression regardless of treat-
ment with IFN-α.138 This evidence demonstrates that the HCV 
population is a vulnerable group generally and that focusing 
on only treatment-associated problems may lead clinicians 
and researchers alike to underestimate those problems that 
are associated with HCV itself.
Limitations of review
The results reported in this review are also limited by a num-
ber of factors. The first one being that only accessible articles 
were included within the review, and those articles that could 
not be accessed due to language constraints or inability to 
access full-text content were not included, which could have 
an impact on the risk factors identified and   discussion of 
these factors.
In addition, there are some risk factors shown to impact on 
rates of depression that do not necessarily fit within the pre-
defined categories and are not readily identifiable at baseline. 
Robaeys et al116 found that vegetative-depressive symptoms at 
week 4 of treatment were predictive of a subsequent diagnosis 
of MDD; however, there were no differences between groups 
at baseline. Likewise, decreased motor speed was associated 
with increased symptoms of depression and fatigue.134
There are also some biological factors that influence IFN-
α-induced depression that were not explored in the literature 
review due to the paucity of literature in that area. One such 
factor is brain-derived neurotrophic factor, which has been 
shown to correlate with BDI scores.139
Other studies have examined risk factors in different 
patient populations. IFN-α is also used as treatment for 
certain cancers such as malignant melanoma,52,140 and there 
are studies within this population that support various risk 
factors that have been examined within this review such as 
HPA axis biomarkers,140 lower levels of tryptophan,52 higher 
pretreatment depression scores,141 low social support, sleep 
disturbance, pessimistic thoughts, and sadness.105
Only those studies that looked at risk factors for depres-
sion were examined. In future, it will be important to deter-
mine what protective factors prevent people from developing Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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a depression. There is some evidence presented that social 
support may be a protective factor against the development 
of depression,24 and further research could determine what 
other protective factors are important.
When interpreting the results from this review, clinicians 
also need to be aware of the individual nature of depression 
and the varying risk factors that will cause each individual 
to become depressed. Even though this review has found 
strong evidence for certain risk factors, this does not mean 
to say that any person who experiences these factors will 
become depressed; it means that they are at a higher risk of 
developing depression than others who do not have these 
risk factors and thus extra assessment and support should 
be administered prior to commencement of treatment in 
those individuals who have been ascertained to be at risk of 
developing depression.
Finally, all results should be interpreted with caution due 
to the differing methodologies and analyses undertaken in 
all the studies within this review. While care has been taken 
to narrow the scope of the review by concentrating only 
on HCV patients, there are still differences between all the 
studies included here. These include the number of patients 
in each study, the type of statistical analysis run, the types 
of depression analysis undertaken (clinician rated and self-
rated, depression scale or clinical diagnosis), and how each 
researcher defined depression (clinical diagnosis or cutoff 
point on depression scale). These should be recognized to be 
limiting factors in interpreting the results of this review.
Conclusions
The current climate of psychiatric research is one where 
there is an acknowledgment of the multidisciplinary 
factors that play into any psychiatric disorder. Current 
research is, therefore, focused on finding interactions between 
genetic, biological, demographic, and psychobehavioral fac-
tors that lead some people to be more vulnerable to devel-
oping psychiatric disorders than others. It would be very 
difficult to identify a single risk factor that would lead people 
to be more susceptible to becoming depressed on IFN-α than 
others. However, the most convincing research conducted 
in this area is that which has examined biological,41,57,58 
genetic,89,91–93 and psychobehavioral41,62,77,92,97 risk factors, and 
it is no surprise that these three risk factors interact with one 
another (for an example of the way these three risk factors 
could interact to produce depression, see Figure 3).
Clinicians and researchers should be wary when trying 
to pinpoint one risk factor to concentrate on when attempt-
ing to identify ‘at-risk’ individuals. Instead, there should be 
an awareness of the complex interplay of biological, psy-
chobehavioral, and genetic factors that lead some people to 
develop depression while taking IFN-α (see Figure 3). Two 
recent studies have examined interactions between genetic 
and psychobehavioral risk factors,92,93 demonstrating the need 
for more translational research in determining the relationship 
between different risk factors. Only when more research of 
this nature has been conducted, more concrete conclusions 
regarding the interaction and importance of individual risk 
factors can be determined.
Clinicians should attempt to assess people fully at base-
line using as many tools available to them, such as depression 
rating scales, sleep disturbance questionnaires, psychiatric 
histories, and biological analysis of tryptophan and/or stress 
hormones. In future, it may also be possible to use genetic 
tools to identify individuals susceptible to development of 
IFN-α-induced depression. HCV-infected patients taking 
IFN-α are undoubtedly a vulnerable population. Effective 
pretreatment screening for baseline risk factors combined 
with more effective support during treatment will enable 
health care workers to better identify patients at risk and 
provide the additional treatment required should   depression 
develop, thus improving adherence rates and improving 
clearance of HCV infection.
Acknowledgments
The authors thank all staff in the Hepatology Centre, in par-
ticular, Barbara Hynes, Clodagh Quinn, and Helena Irish, as 
well as the Psychological Services Department at St James’s 
Biological
vulnerability
(eg, lower tryptophan)
Genetic
vulnerability
(eg, short allele 5-HTTLPR)
Depression
IFN-α
Psychiatric
vulnerability
(eg, increased baseline
depression score)
Figure 3 interaction of risk factors. Model by which various risk factors could 
interact to possibly produce depression in those patients taking iFN-α. it is possible 
that administration of iFN-α could lead to some underlying genetic vulnerability 
(eg, the short allele in 5-HTLLPR) impacting upon levels of a chemical such as 
tryptophan. This vulnerability, along with the biological response it could induce, 
would also interact with a psychiatric vulnerability. As these people have the genetic 
vulnerability, they are more likely to be depressed at baseline and/or have had a 
history of psychiatric disorders. All this would lead the person to be vulnerable to 
developing depression following administration of iFN.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
289
interferon-α and depression risk factors
Hospital, for their help in allowing us to better understand 
the patients’ perspective of taking IFN-α. Supported by the 
Health Research Board (Ireland).
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C 
virus infection. Lancet Infect Dis. 2005;5(9):558–567.
  2.  Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 
2003;362(9401):2095–2100.
  3.  Esteban JI, Sauleda S, Quer J. The changing epidemiology of 
hepatitis C virus infection in Europe. J Hepatol. 2008;48(1):148–162.
  4.  Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B 
and C in Europe – a review. Euro Surveill. 2008;13(21). Available from: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18880. 
Accessed 2010 Sep 18.
  5.  Alter MJ. Epidemiology of hepatitis C virus infection. World J 
  Gastroenterol. 2007;13(17):2436–2441.
  6.  Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: 
outcome of compensated cirrhosis due to chronic hepatitis C infection. 
Aliment Pharmacol Ther. 2010;32(3):344–355.
  7.  Leone N, Rizzetto M. Natural history of hepatitis C virus infection: 
from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.   Minerva 
Gastroenterol Dietol. 2005;51(1):31–46.
  8.  Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic 
hepatitis C infection. BMJ. 2006;332(7548):1013–1017.
  9.  Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future 
complications of chronic hepatitis C in the United States. Liver Transpl. 
2003;9(4):331–338.
  10.  Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How 
cells respond to interferons. Annu Rev Biochem. 1998;67:227–264.
  11.  Bacon BR. Managing hepatitis C. Am J Manag Care. 2004;10 Suppl 2: 
S30–S40.
  12.  Davis GL, Esteban-Mur R, Rustgi V , et al. Interferon alfa-2b alone or 
in combination with ribavirin for the treatment of relapse of chronic 
hepatitis C. International Hepatitis Interventional Therapy Group. 
N Engl J Med. 1998;339(21):1493–1499.
  13.  Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, 
  Carithers RL Jr. Pretreatment symptoms and dosing regimen predict 
side-effects of interferon therapy for hepatitis C. J Viral Hepat. 2000; 
7(3):211–217.
  14.  Foster G, Mathurin P. Hepatitis C virus therapy to date. Antivir Ther. 
2008;13 Suppl 1:S3–S8.
  15.  Kowdley KV. Hematologic side effects of interferon and ribavirin 
therapy. J Clin Gastroenterol. 2005;39 Suppl 1:S3–S8.
  16.  Ong JP, Younossi ZM. Managing the hematologic side effects of 
antiviral therapy for chronic hepatitis C: anemia, neutropenia, and 
thrombocytopenia. Cleve Clin J Med. 2004;71 Suppl 3:S17–S21.
  17.  Capuron L, Miller AH. Cytokines and psychopathology: lessons from 
interferon-alpha. Biol Psychiatry. 2004;56(11):819–824.
  18.  Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associ-
ated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 
2000;157(6):867–876.
  19.  Fukunishi K, Tanaka H, Maruyama J, et al. Burns in a suicide attempt related 
to psychiatric side effects of interferon. Burns. 1998;24(6): 581–583.
  20.  Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associ-
ated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 
1994;21(2):241–243.
  21.  McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone 
or in combination with ribavirin as initial treatment for chronic hepa-
titis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 
339(21):1485–1492.
  22.  Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Rela-
tionship of health-related quality of life to treatment adherence 
and sustained response in chronic hepatitis C patients. Hepatology. 
2002;35(3):704–708.
  23.  Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M. Compli-
ance with therapy in patients with chronic hepatitis C: associations with 
psychiatric symptoms, interpersonal problems, and mode of acquisition. 
Dig Dis Sci. 2001;46(10):2060–2065.
  24.  Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, 
Fried MW. Prospective analysis of depression during peginterferon 
and ribavirin therapy of chronic hepatitis C: results of the Virahep-C 
study. Am J Gastroenterol. 2009;104(12):2949–2958.
  25.  Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced 
depression in chronic hepatitis C with citalopram: a randomised, double-
blind, placebo-controlled study. Gut. 2008;57(4):531–536.
  26.  Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse 
of major depression during interferon-alpha therapy for hepatitis C – a 
pilot study. Dig Dis Sci. 2007;52(10):2557–2563.
  27.  Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for 
prevention of depressive symptoms induced by interferon-alpha 
and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10): 
1163–1174.
  28.  Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A 
randomized trial of paroxetine to prevent interferon-alpha-induced depres-
sion in patients with hepatitis C. J Affect Disord. 2007;103(1–3): 83–90.
  29.  Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-
alpha associated depression in psychiatric risk patients with chronic 
hepatitis C. J Hepatol. 2005;42(6):793–798.
  30.  Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and men-
tal side effects during hepatitis C treatment with interferon alfa 
and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2): 
443–451.
  31.  Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment 
with interferon-alpha in patients with chronic hepatitis and mood or 
anxiety disorders. Lancet. 1999;354(9173):131–132.
  32.  Dantzer R, Bluthe RM, Gheusi G, et al. Molecular basis of sickness 
behavior. Ann N Y Acad Sci. 1998;856:132–138.
  33.  Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From 
inflammation to sickness and depression: when the immune system 
subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.
  34.  Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness 
  behaviour: mechanisms and implications. Trends Neurosci. 2002; 
25(3):154–159.
  35.  Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of 
depression: what can we learn from animal studies? Neurosci Biobehav 
Rev. 2005;29(4–5):891–909.
  36.  Hart BL. Biological basis of the behavior of sick animals. Neurosci 
Biobehav Rev. 1988;12(2):123–137.
  37.  Charlton BG. The malaise theory of depression: major depressive 
disorder is sickness behavior and antidepressants are analgesic. Med 
Hypotheses. 2000;54(1):126–130.
  38.  Lotrich FE. Major depression during interferon-alpha treatment: 
vulnerability and prevention. Dialogues Clin Neurosci. 2009;11(4): 
417–425.
  39.  Schiepers OJ, Wichers MC, Maes M. Cytokines and major depres-
sion. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2): 
201–217.
  40.  Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with 
interferon-alpha in patients affected by chronic hepatitis C induces an 
intercorrelated stimulation of the cytokine network and an increase 
in depressive and anxiety symptoms. Psychiatry Res. 2001;105(1–2): 
45–55.
  41.  Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced 
depression during IFN-alpha treatment: the role of IL-6 and sleep qual-
ity. Brain Behav Immun. 2009;23(8):1109–1116.
  42.  Loftis JM, Hauser P. The phenomenology and treatment of interferon-
induced depression. J Affect Disord. 2004;82(2):175–190.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
290
Smith et al
  43.  Maddock C, Landau S, Barry K, et al. Psychopathological symptoms 
during interferon-alpha and ribavirin treatment: effects on virologic 
response. Mol Psychiatry. 2005;10(4):332–333.
  44.  Capuron L, Dantzer R, Miller AH. Neuro-immune interactions in psy-
chopathology with the example of interferon-alpha-induced depression. 
J Soc Biol. 2003;197(2):151–156.
  45.  Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) 
and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol 
Psychiatry. 2002;26(4):731–746.
  46.  Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of inter-
feron therapy: prevalence, proposed mechanisms, and future directions. 
J Clin Oncol. 2000;18(11):2316–2326.
  47.  Loftis JM, Huckans M, Morasco BJ. Neuroimmune mechanisms of 
cytokine-induced depression: current theories and novel treatment 
strategies. Neurobiol Dis. 2010;37(3):519–533.
  48.  Elhwuegi AS. Central monoamines and their role in major depres-
sion. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3): 
435–451.
  49.  Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology 
of depression: focus on the serotonin transporter. Clin Chem. 1994; 
40(2):288–295.
  50.  Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. 
  Neurobiology of depression: an integrated view of key findings. Int J 
Clin Pract. 2007;61(12):2030–2040.
  51.  Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T. A link 
between stress and depression: shifts in the balance between the kynure-
nine and serotonin pathways of tryptophan metabolism and the etiology 
and pathophysiology of depression. Stress. 2008;11(3):198–209.
  52.  Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced 
changes in tryptophan metabolism. relationship to depression and 
paroxetine treatment. Biol Psychiatry. 2003;54(9):906–914.
  53.  Bonaccorso S, Marino V , Puzella A, et al. Increased depressive rat-
ings in patients with hepatitis C receiving interferon-alpha-based 
immunotherapy are related to interferon-alpha-induced changes 
in the serotonergic system. J Clin Psychopharmacol. 2002;22(1): 
86–90.
  54.  Maes M, Bonaccorso S, Marino V , et al. Treatment with interferon-
alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl 
peptidase IV activity, which is related to IFN alpha-induced depres-
sive and anxiety symptoms and immune activation. Mol Psychiatry. 
2001;6(4):475–480.
  55.  Fontana RJ, Kronfol Z, Lindsay KL, et al. Changes in mood states and 
biomarkers during peginterferon and ribavirin treatment of chronic 
hepatitis C. Am J Gastroenterol. 2008;103(11):2766–2775.
  56.  Russo S, Kema IP, Haagsma EB, et al. Irritability rather than depression 
during interferon treatment is linked to increased tryptophan catabolism. 
Psychosom Med. 2005;67(5):773–777.
  57.  Raison CL, Borisov AS, Majer M, et al. Activation of central ner-
vous system inflammatory pathways by interferon-alpha: relation-
ship to monoamines and depression. Biol Psychiatry. 2009;65(4): 
296–303.
  58.  Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain 
tryptophan and kynurenines during immune stimulation with IFN-alpha: 
relationship to CNS immune responses and depression. Mol Psychiatry. 
2010;15(4):393–403.
  59.  Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the 
treatment of interferon-alpha-induced depression in chronic hepatitis C. 
Aliment Pharmacol Ther. 2002;16(6):1091–1099.
  60.  Dafny N, Yang PB. Interferon and the central nervous system. Eur J 
Pharmacol. 2005;523(1–3):1–15.
  61.  Asnis GM, de La Garza R 2nd. Interferon-induced depression in 
chronic hepatitis C: a review of its prevalence, risk factors, biol-
ogy, and treatment approaches. J Clin Gastroenterol. 2006;40(4): 
322–335.
  62.  Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegy-
lated interferon-alpha plus ribavirin therapy: prevalence and prediction. 
J Clin Psychiatry. 2005;66(1):41–48.
  63.  Leonard BE. The HPA and immune axes in stress: the involvement of the 
serotonergic system. Eur Psychiatry. 2005;20 Suppl 1:S302–S306.
  64.  Anisman H. Cascading effects of stressors and inflammatory immune 
system activation: implications for major depressive disorder.   
J   Psychiatry Neurosci. 2009;34(1):4–20.
  65.  Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflamma-
tion and the pathogenesis of depression. Trends Immunol. 2006;27(1): 
24–31.
  66.  Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M. 
Interferon-alpha-induced depressive symptoms are related to changes in 
the cytokine network but not to cortisol. J Psychosom Res. 2007;62(2): 
207–214.
  67.  Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH. 
Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis 
activity: relationship with proinflammatory cytokines and behavior. Mol 
Psychiatry. 2010;15(5):535–547.
  68.  Maier SF, Watkins LR. Cytokines for psychologists: implications 
of bidirectional immune-to-brain communication for understanding 
behavior, mood, and cognition. Psychol Rev. 1998;105(1):83–107.
  69.  Begley DJ. The interaction of some centrally active drugs with the 
blood-brain barrier and circumventricular organs. Prog Brain Res. 
1992;91:163–169.
  70.  Ermisch A, Brust P, Kretzschmar R, Ruhle HJ. Peptides and blood-brain 
barrier transport. Physiol Rev. 1993;73(3):489–527.
  71.  Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and 
serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp 
Ther. 1992;261(3):964–969.
  72.  Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor 
alpha is transported from blood to brain in the mouse. J Neuroimmunol. 
1993;47(2):169–176.
  73.  Brown MD, Wick TM, Eckman JR. Activation of vascular endothelial 
cell adhesion molecule expression by sickle blood cells. Pediatr Pathol 
Mol Med. 2001;20(1):47–72.
  74.  Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant 
of depressive illness: animal and human studies. Curr Pharm Des. 
2005;11(8):963–972.
  75.  Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of 
clinical depression: stressor- and cytokine-induced alterations of 
  neuroplasticity. Neuroscience. 2005;135(3):659–678.
  76.  Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline 
immune activation as a risk factor for the onset of depression during 
interferon-alpha treatment. Biol Psychiatry. 2006;60(1):77–79.
  77.  Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor 
sleep quality predicts onset of either major depression or subsyndromal 
depression with irritability during interferon-alpha treatment.   Psychiatry 
Res. 2010;177(1–2):240–245.
  78.  Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on 
  depression: moderation by a polymorphism in the 5-HTT gene. Science. 
2003;301(5631):386–389.
  79.  Brown GW, Harris TO. Depression and the serotonin transporter 
5-HTTLPR polymorphism: a review and a hypothesis concerning 
gene-environment interaction. J Affect Disord. 2008;111(1):1–12.
  80.  Hoefgen B, Schulze TG, Ohlraun S, et al. The power of sample size 
and homogenous sampling: association between the 5-HTTLPR sero-
tonin transporter polymorphism and major depressive disorder. Biol 
Psychiatry. 2005;57(3):247–251.
  81.  Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR 
polymorphism impacts human cingulate-amygdala interactions: 
a genetic susceptibility mechanism for depression. Nat Neurosci. 
2005;8(6):828–834.
  82.  Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 
are associated with increased recurrence of depressive episodes and 
rapid response to antidepressant treatment. Nat Genet. 2004;36(12): 
1319–1325.
  83.  Tadokoro K, Hashimoto R, Tatsumi M, Kosuga A, Kamijima K, 
Kunugi H. The gem interacting protein (GMIP) gene is associated with 
major depressive disorder. Neurogenetics. 2005;6(3):127–133.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
291
interferon-α and depression risk factors
  84.  Heiman GA, Ottman R, Saunders-Pullman RJ, Ozelius LJ, Risch NJ, 
Bressman SB. Increased risk for recurrent major depression in DYT1 
dystonia mutation carriers. Neurology. 2004;63(4):631–637.
  85.  Lemonde S, Turecki G, Bakish D, et al. Impaired repression at 
a 5-hydroxytryptamine 1A receptor gene polymorphism associ-
ated with major depression and suicide. J Neurosci. 2003;23(25):   
8788–8799.
  86.  Rosa A, Peralta V , Papiol S, et al. Interleukin-1beta (IL-1beta) gene 
and increased risk for the depressive symptom-dimension in schizo-
phrenia spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 
2004;124B(1):10–14.
  87.  Levinson DF. The genetics of depression: a review. Biol Psychiatry. 
2006;60(2):84–92.
  88.  Shyn SI, Hamilton SP. The genetics of major depression: moving 
beyond the monoamine hypothesis. Psychiatr Clin North Am. 2010; 
33(1):125–140.
  89.  Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms 
in the interleukin-6 and serotonin transporter genes, and depression 
and fatigue induced by interferon-alpha and ribavirin treatment. Mol 
Psychiatry. 2009;14(12):1095–1104.
  90.  Gochee PA, Powell EE, Purdie DM, et al. Association between 
apolipoprotein E epsilon4 and neuropsychiatric symptoms during 
interferon alpha treatment for chronic hepatitis C. Psychosomatics. 
2004;45(1):49–57.
  91.  Kraus MR, Al-Taie O, Schafer A, Pfersdorff M, Lesch KP, 
  Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts 
interferon-induced depression in chronic hepatitis C.   Gastroenterology. 
2007;132(4):1279–1286.
  92.  Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depres-
sion during interferon-alpha treatment is affected by the serotonin 
transporter polymorphism. Biol Psychiatry. 2009;65(4):344–348.
  93.  Pierucci-Lagha A, Covault J, Bonkovsky HL, et al. A functional 
serotonin transporter gene polymorphism and depressive effects asso-
ciated with interferon-alpha treatment. Psychosomatics. 2010;51(2): 
137–148.
  94.  Su KP, Huang SY, Peng CY, et al. Phospholipase A2 and cyclooxyge-
nase 2 genes influence the risk of interferon-alpha-induced depression 
by regulating polyunsaturated fatty acids levels. Biol Psychiatry. 
2010;67(6):550–557.
  95.  Yoshida K, Alagbe O, Wang X, et al. Promoter polymorphisms of the 
interferon-alpha receptor gene and development of Interferon-induced 
depressive symptoms in patients with chronic hepatitis C: preliminary 
findings. Neuropsychobiology. 2005;52(2):55–61.
  96.  Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Labile anger 
during interferon alfa treatment is associated with a polymorphism 
in tumor necrosis factor alpha. Clin Neuropharmacol. 2010;33(4): 
191–197.
  97.  Castera L, Constant A, Henry C, et al. Impact on adherence and 
sustained virological response of psychiatric side effects during 
peginterferon and ribavirin therapy for chronic hepatitis C. Aliment 
Pharmacol Ther. 2006;24(8):1223–1230.
  98.  Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical 
course of major depression in patients with chronic hepatitis type C 
undergoing interferon-alpha therapy: a prospective study. Gen Hosp 
Psychiatry. 2003;25(1):34–38.
  99.  Hauser P, Khosla J, Aurora H, et al. A prospective study of the 
incidence and open-label treatment of interferon-induced major 
depressive disorder in patients with hepatitis C. Mol Psychiatry. 
2002;7(9):942–947.
  100.  Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. 
Depression from interferon therapy in patients with hepatitis C. Am J 
Psychiatry. 1999;156(7):1120.
  101.  Martin-Santos R, Diez-Quevedo C, Castellvi P, et al. De novo 
depression and anxiety disorders and influence on adher-
ence   during peginterferon-alpha-2a and ribavirin treatment in 
patients with hepatitis C. Aliment Pharmacol Ther. 2008;27(3): 
257–265.
  102.  Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, 
Garre JB. Hepatitis C, alpha interferon, anxiety and depression 
  disorders: a prospective study of 71 patients. World J Biol Psychiatry. 
2003;4(3):115–118.
  103.  Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes 
M. Depression induced by treatment with interferon-alpha in 
patients affected by hepatitis C virus. J Affect Disord. 2002;72(3): 
237–241.
  104.  Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression fol-
lowing pegylated interferon-alpha: characteristics and vulnerability. 
J Psychosom Res. 2007;63(2):131–135.
  105.  Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psy-
chosocial characteristics of patients developing depressive symptoms 
during interleukin-2 and/or interferon-alpha cancer therapy. Brain 
Behav Immun. 2004;18(3):205–213.
  106.  Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of 
interferon alfa-2b in patients with chronic hepatitis C: a randomized 
multicenter trial. Hepatitis Interventional Therapy Group. Hepatology. 
1996;24(5):1034–1040.
  107.  Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose 
interferon therapy for chronic hepatitis C. J Hepatol. 1996;25(3): 
283–291.
  108.  Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a 
plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 
2002;347(13):975–982.
  109.  Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Inter-
feron treatment is not associated with a worsening of psychiatric 
symptoms in patients with hepatitis C. J Gastroenterol Hepatol. 
2002;15(3):300–303.
  110.  Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complica-
tions of long-term interferon alfa therapy. Arch Intern Med. 
1987;147(9):1577–1580.
  111.  Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito 
L, Rampello L. Interferon alpha-induced depression in chronic 
hepatitis C patients: comparison between different types of interferon 
alpha. Neuropsychobiology. 1998;37(2):93–97.
  112.  Iino S. High dose interferon treatment in chronic hepatitis C. Gut. 
1993;34 Suppl 2:S114–S118.
  113.  Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects 
of pegylated interferon alfa-2b as compared to conventional interferon 
alfa-2b in patients with chronic hepatitis C. World J Gastroenterol. 
2005;11(12):1769–1774.
  114.  Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b 
plus ribavirin compared with interferon alfa-2b plus ribavirin for 
initial treatment of chronic hepatitis C: a randomised trial. Lancet. 
2001;358(9286):958–965.
  115.  Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a 
in patients with chronic hepatitis C. N Engl J Med. 2000;343(23): 
1666–1672.
  116.  Robaeys G, de Bie J, Wichers MC, et al. Early prediction of major 
depression in chronic hepatitis C patients during peg-interferon 
alpha-2b treatment by assessment of vegetative-depressive 
symptoms after four weeks. World J Gastroenterol. 2007;13(43): 
5736–5740.
  117.  Quarantini LC, Bressan RA, Galvao A, Batista-Neves S, Parana R, Miran-
da-Scippa A. Incidence of psychiatric side effects   during pegylated 
interferon- alpha retreatment in nonresponder   hepatitis C virus-infected 
patients. Liver Int. 2007;27(8):1098–1102.
  118.  Amodio P, de Toni EN, Cavalletto L, et al. Mood, cognition and EEG 
changes during interferon alpha (alpha-IFN) treatment for chronic 
hepatitis C. J Affect Disord. 2005;84(1):93–98.
  119.  Bannink M, Fekkes D, van Gool AR, et al. Interferon-alpha influences 
tryptophan metabolism without inducing psychiatric side effects. 
Neuropsychobiology. 2007;55(3–4):225–231.
  120.  Donnelly S. Patient management strategies for interferon alfa-2b 
as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum. 
1998;25(5):921–927.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
292
Smith et al
  121.  Capuron L, Ravaud A. Prediction of the depressive effects of inter-
feron alfa therapy by the patient’s initial affective state. N Engl J Med. 
1999;340(17):1370.
  122.  Castellvi P, Navines R, Gutierrez F, et al. Pegylated interferon and 
ribavirin-induced depression in chronic hepatitis C: role of personality. 
J Clin Psychiatry. 2009;70(6):817–828.
  123.  Dell’Osso L, Pini S, Maggi L, et al. Subthreshold mania as predic-
tor of depression during interferon treatment in HCV+ patients 
without current or lifetime psychiatric disorders. J Psychosom Res. 
2007;62(3):349–355.
  124.  Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Inci-
dence of interferon alfa-induced depression in patients with chronic 
hepatitis C. Hepatology. 2002;35(4):978–979.
  125.  Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study 
of neuropsychiatric symptoms associated with interferon-alpha-2b and 
ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 
2003;44(2):104–112.
  126.  Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E.   
Influence of psychiatric diagnoses on interferon-alpha treatment for 
chronic hepatitis C in a veteran population. Am J Gastroenterol. 
2001;96(1):157–164.
  127.  Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric 
adverse effects of interferon-alpha: recognition and management. CNS 
Drugs. 2005;19(2):105–123.
  128.  Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-
related quality of life in chronic hepatitis C. J Hepatol. 2006;44(3): 
491–498.
  129.  Fontana RJ, Bieliauskas LA, Lindsay KL, et al. Cognitive function 
does not worsen during pegylated interferon and ribavirin retreatment 
of chronic hepatitis C. Hepatology. 2007;45(5):1154–1163.
  130.  Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. 
Emotional distress during interferon-alpha-2B and ribavirin treatment 
of chronic hepatitis C. Psychosomatics. 2002;43(5):378–385.
  131.  Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. 
Effect of interferon-alpha treatment of chronic hepatitis C on health-
related quality of life. Dig Dis Sci. 1997;42(12):2482–2486.
  132.  Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric 
symptoms in patients with chronic hepatitis C receiving interferon 
alfa-2b therapy. J Clin Psychiatry. 2003;64(6):708–714.
  133.  Maddock C, Baita A, Orru MG, et al. Psychopharmacological treat-
ment of depression, anxiety, irritability and insomnia in patients 
receiving interferon-alpha: a prospective case series and a discussion 
of biological mechanisms. J Psychopharmacol. 2004;18(1):41–46.
  134.  Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL, Miller AH. 
IFN-alpha-induced motor slowing is associated with increased 
  depression and fatigue in patients with chronic hepatitis C. Brain 
Behav Immun. 2008;22(6):870–880.
  135.  Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological 
approaches in the assessment of interferon-alfa-induced depression 
in patients with chronic hepatitis C – a critical review. Int J Methods 
Psychiatr Res. 2007;16(4):186–201.
  136.  Yovtcheva SP, Rifai MA, Moles JK, van der Linden BJ. Psychiatric 
comorbidity among hepatitis C-positive patients. Psychosomatics. 
2001;42(5):411–415.
  137.  Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety. 
1998;7(4):188–193.
  138.  Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and 
depression in drug users. Am J Gastroenterol. 1998;93(5):785–789.
  139.  Kenis G, Prickaerts J, van Os J, et al. Depressive symptoms following 
interferon-alpha therapy: mediated by immune-induced reductions 
in brain-derived neurotrophic factor? Int J Neuropsychopharmacol. 
2010 Jul 29;1–7. Epub 2010 Sep 1.
  140.  Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, 
Miller AH. Association of exaggerated HPA axis response to the initial 
injection of interferon-alpha with development of depression during 
interferon-alpha therapy. Am J Psychiatry. 2003;160(7):1342–1345.
  141.  Heinze S, Egberts F, Rotzer S, et al. Depressive mood changes and 
psychiatric symptoms during 12-month low-dose interferon-alpha 
treatment in patients with malignant melanoma: results from the 
multicenter DeCOG trial. J Immunother. 2010;33(1):106–114.
  142.  Sockalingam S, Abbey SE, Alosaimi F, Novak M. A review of sleep 
disturbance in hepatitis C. J Clin Gastroenterol. 2010;44(1):38–45.